We serve Chemical Name:4-(2-methyl-1,3-thiazol-4-yl)butan-1-amine CAS:325491-81-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-(2-methyl-1,3-thiazol-4-yl)butan-1-amine
CAS.NO:325491-81-4
Synonyms:2-methyl-4-thiazolebutanamine
Molecular Formula:C8H14N2S
Molecular Weight:170.27500
HS Code:2934100090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:282.808ºC at 760 mmHg
Density:1.078g/cm3
Index of Refraction:1.545
PSA:67.15000
Exact Mass:170.08800
LogP:2.43320
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-methyl-4-thiazolebutanamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-methyl-4-thiazolebutanamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-methyl-4-thiazolebutanamine Use and application,2-methyl-4-thiazolebutanamine technical grade,usp/ep/jp grade.
Related News: US citizens who’ve been in other parts of mainland China in the last 14 days will undergo screening at US ports of entry and up to 14 days of self-monitoring. 4-(2-methyl-1,3-thiazol-4-yl)butan-1-amine manufacturer ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy. 4-(2-methyl-1,3-thiazol-4-yl)butan-1-amine supplier US citizens who’ve been in other parts of mainland China in the last 14 days will undergo screening at US ports of entry and up to 14 days of self-monitoring. 4-(2-methyl-1,3-thiazol-4-yl)butan-1-amine vendor Government prosecutors often consider whether a corporation made a genuine effort to investigate and address potentially illegal activities once learning of them. 4-(2-methyl-1,3-thiazol-4-yl)butan-1-amine factory ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.
